Sinonasal malignancies make up< 5% of all head and neck neoplasms, with an incidence of
0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas …

Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …

Purpose To provide guidance to clinicians regarding therapy for patients with brain
metastases from solid tumors. Methods ASCO convened an Expert Panel and conducted a …

How targeted therapies and immunotherapies shape tumors, and thereby influence
subsequent therapeutic responses, is poorly understood. In the present study, we show, in …

Skin cancer affects the lives of millions of people every year, as it is considered the most
popular form of cancer. In the USA alone, approximately three and a half million people are …

PURPOSE To provide guidance to clinicians regarding the use of systemic therapy for
melanoma. METHODS American Society of Clinical Oncology convened an Expert Panel …

With the burgeoning use of immune-based treatments for cancer, never has there been a
greater need to understand the tumour microenvironment within which immune cells …

PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits
on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the …

We are currently witnessing a worldwide increase in the incidence of melanoma. Incidence
in Europe is about 25 cases per 100,000 population, while in Australia it reaches a rate of 60 …